The prevailing Pediatric Neuroblastoma Treatment Market trends are dominated by the increasing clinical acceptance and application of immunotherapy across various risk groups. The successful incorporation of anti-GD2 monoclonal antibodies into standard treatment for high-risk neuroblastoma has created a paradigm shift, and the market is now trending toward next-generation immunotherapy,...